An FDA advisory panel starts a two-day meeting to discuss Avandia, GlaxoSmithKline's (GSK +0.4%)...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

An FDA advisory panel starts a two-day meeting to discuss Avandia, GlaxoSmithKline's (GSK +0.4%) former blockbuster diabetes pill whose sales plummeted after the agency said in 2010 that it could only be used only in rare cases due to fears that it caused heart attacks. The options are to remove, modify or leave Avandia's safety restrictions in place, or withdraw the drug entirely. However, even if the FDA eases those restrictions, sales of Avandia aren't expected to significantly increase. (Webcast)